CIK 0001595097 · Non-accelerated filer<br>Smaller reporting company
Corbus Pharmaceuticals Holdings, Inc.
Sign in to watch- Ticker
- CRBP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464348039
- Phone
- 617-963-0103
- Business address
- 500 RIVER RIDGE DRIVE, NORWOOD, MA, 02062
- Former names
- SAV Acquisition Corp
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,758,438
- in 2 filings, $16K under 10b5-1 plans
Net −$1,758,438. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-12-11 | Cormorant Asset Management, LP 10% owner | Sale | −30,029 | $11.46 | $344K | 2,344,971 |
| 2025-10-27 | Cohen Yuval Chief Executive Officer | Option exercise 10b5-1 | +8,973 | $4.26 | $38K | 147,160 |
| 2025-10-27 | Cohen Yuval Chief Executive Officer | Sale 10b5-1 | −8,973 | $17.14 | $154K | 138,187 |
| 2025-10-27 | Cohen Yuval Chief Executive Officer | Option exercise · Stock options (right to buy) 10b5-1 | −8,973 | 22,106 | ||
| 2025-10-24 | Cohen Yuval Chief Executive Officer | Option exercise 10b5-1 | +18,660 | $4.26 | $79K | 156,847 |
| 2025-10-24 | Cohen Yuval Chief Executive Officer | Sale 10b5-1 | −18,660 | $17.01 | $317K | 138,187 |
| 2025-10-24 | Cohen Yuval Chief Executive Officer | Option exercise · Stock options (right to buy) 10b5-1 | −18,660 | 31,079 | ||
| 2025-10-24 | Moran Sean F. Chief Financial Officer | Option exercise 10b5-1 | +12,981 | $4.26 | $55K | 86,294 |
| 2025-10-24 | Moran Sean F. Chief Financial Officer | Sale 10b5-1 | −12,981 | $17.02 | $221K | 73,313 |
| 2025-10-24 | Moran Sean F. Chief Financial Officer | Option exercise · Stock options (right to buy) 10b5-1 | −12,981 | 10,386 | ||
| 2025-10-20 | Altmeyer Anne Director | Option exercise 10b5-1 | +1,060 | $4.80 | $5K | 7,251 |
| 2025-10-20 | Altmeyer Anne Director | Sale 10b5-1 | −1,060 | $20.50 | $22K | 6,191 |
| 2025-10-20 | Altmeyer Anne Director | Option exercise · Stock options (right to buy) 10b5-1 | −1,060 | 4,247 | ||
| 2025-05-30 | Kung Winston Director | Grant or award | +4,800 | 10,366 | ||
| 2025-05-30 | Kung Winston Director | Grant or award · Stock options (right to buy) | +16,000 | 16,000 | ||
| 2025-05-30 | Ben Yong Director | Grant or award | +4,800 | 7,583 | ||
| 2025-05-30 | Ben Yong Director | Grant or award · Stock options (right to buy) | +16,000 | 16,000 | ||
| 2025-05-30 | Jenkins John Kenneth Director | Sale 10b5-1 | −2,783 | $7.35 | $20K | 33 |
| 2025-05-30 | Jenkins John Kenneth Director | Grant or award 10b5-1 | +4,800 | 4,833 | ||
| 2025-05-30 | Jenkins John Kenneth Director | Grant or award · Stock options (right to buy) 10b5-1 | +16,000 | 16,000 |
Page 3 of 10 · 200 trades